INONasdaqPharmaceutical PreparationsFiscal year ends December 31
INOVIO PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.00+0.01 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $81.62M
- P/E (TTM)
- –
- Dividend yield
- –
Inovio Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $103.40M | $166.30M |
| Enterprise Value | $66.70M | $88.19M |
| PB Ratio | 23.65 | 2.03 |
| P/TBV Ratio | 23.65 | 2.29 |
Income (trailing twelve months)
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $0 | $58.34M |
| Operating Income | -$79.26M | -$21.40M |
| Net Income | -$67.43M | -$22.46M |
| EBITDA | -$79.26M | -$16.91M |
| EPS (Diluted) | -$1.16 | -$0.83 |
Returns
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -409.9% | -53.2% |
| Return on Assets (ROA) | -114.6% | -40.9% |
| Return on Capital Employed (ROCE) | -836.6% | -38.1% |
Growth
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -100.0% | 5.96% |
| Revenue Growth (3Y CAGR) | -81.5% | 2.25% |
| Revenue Growth (5Y CAGR) | -61.2% | 6.48% |
Balance sheet
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $36.70M | $61.43M |
| Net Cash (Debt) | $36.70M | $15.35M |
| Net Cash Per Share | $0.35 | $0.66 |
| Equity (Book Value) | $4.37M | $49.09M |
| Book Value Per Share | $0.04 | $1.37 |
| Tangible Book Value | $4.37M | $23.52M |
| Working Capital | -$1.81K | $76.81M |
Financial position
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 1.00 | 3.34 |
| Quick Ratio | 0.92 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$80.58M | -$12.35M |
| Capital Expenditures | -$195.40K | -$1.08M |
| Free Cash Flow | -$80.78M | -$20.22M |
| FCF Per Share | -$0.78 | -$0.42 |
Efficiency
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $0 | $404.87K |
| Profits Per Employee | -$2.50M | -$703.34K |
| Employee Count | 27 | 74 |
Dividends and yields
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -65.2% | -23.3% |
| FCF Yield | -78.1% | -8.72% |
| Buyback Yield | -36.9% | -0.59% |
| Shareholder Yield | -36.9% | 0.00% |
Shares
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 103,398,000 | 58,127,000 |
| Shares Change (YoY) | 95.4% | 10.9% |
| Shares Change (QoQ) | 18.0% | 0.54% |
| Float | 103,001,000 | 49,136,700 |
| Shares Held by Insiders | 0.38% | 11.6% |
| Shares Held by Institutions | 31.7% | 59.4% |
Scores
| Measure | Inovio Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -56.10 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Inovio Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.